These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 17263798

  • 21. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
    Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, Berne B, Figueiredo A, Austad J.
    J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.
    Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S.
    Br J Dermatol; 2009 Jul; 161(1):159-66. PubMed ID: 19416259
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial.
    Ortonne JP, Ganslandt C, Tan J, Nordin P, Kragballe K, Segaert S.
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):919-26. PubMed ID: 19453810
    [Abstract] [Full Text] [Related]

  • 25. Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic.
    Takahashi H, Satoh K, Takagi A, Iizuka H.
    J Dermatol; 2017 Sep; 44(9):1024-1026. PubMed ID: 28406531
    [Abstract] [Full Text] [Related]

  • 26. [Psoriasis].
    el Sayed F, Marguery MC.
    Ann Dermatol Venereol; 1997 Sep; 124(1):91-101. PubMed ID: 9686048
    [No Abstract] [Full Text] [Related]

  • 27. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
    Asche CV, Kim M, Feldman SR, Zografos P, Lu M.
    J Med Econ; 2017 Sep; 20(9):1000-1006. PubMed ID: 28581873
    [Abstract] [Full Text] [Related]

  • 28. Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate.
    Hino R, Kabashima R, Kawakami C, Sugita K, Nakamura M, Tokura Y.
    J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):242-4. PubMed ID: 20477915
    [No Abstract] [Full Text] [Related]

  • 29. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
    van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L.
    Br J Dermatol; 2009 Jan; 160(1):170-6. PubMed ID: 19067709
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of simple onycholysis: an open-label study.
    Park JM, Mun JH, Jwa SW, Song M, Kim HS, Ko HC, Kim BS, Kim MB.
    J Am Acad Dermatol; 2013 Sep; 69(3):492-3. PubMed ID: 23957979
    [No Abstract] [Full Text] [Related]

  • 32. Combining traditional systemic and biologic therapies for psoriasis.
    Heffernan MP.
    Semin Cutan Med Surg; 2010 Mar; 29(1):67-9. PubMed ID: 20430311
    [Abstract] [Full Text] [Related]

  • 33. Calcipotriol in psoriasis vulgaris: a controlled trial comparing betamethasone dipropionate + salicylic acid.
    Crosti C, Finzi AF, Mian E, Scarpa C.
    Int J Dermatol; 1997 Jul; 36(7):537-9. PubMed ID: 9268756
    [No Abstract] [Full Text] [Related]

  • 34. In vitro compatibility of tazarotene with other topical treatments of psoriasis.
    Hecker D, Worsley J, Yueh G, Lebwohl M.
    J Am Acad Dermatol; 2000 Jun; 42(6):1008-11. PubMed ID: 10827404
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Calcipotriol-betamethasone ointment versus calcipotriol ointment in the treatment of psoriasis vulgaris.
    Duweb G, Alhaddar J, Elsherif B, Eljehawi N, Makhlouf H.
    Drugs Exp Clin Res; 2005 Jun; 31(5-6):175-9. PubMed ID: 16425973
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris.
    Parslew R, Traulsen J.
    Eur J Dermatol; 2005 Jun; 15(1):37-9. PubMed ID: 15701591
    [Abstract] [Full Text] [Related]

  • 39. The right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments.
    Savary J, Ortonne JP, Aractingi S.
    J Eur Acad Dermatol Venereol; 2005 Nov; 19 Suppl 3():14-7. PubMed ID: 16274407
    [Abstract] [Full Text] [Related]

  • 40. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
    Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, Martini P, Peris K, Peserico A, Chimenti S.
    J Dermatolog Treat; 2007 Nov; 18(6):361-5. PubMed ID: 17934937
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.